Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005060
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 15, 2012
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with surgery may kill more tumor cells. It is not yet known if chemotherapy followed by surgery is more effective than surgery followed by chemotherapy for stomach cancer.

PURPOSE: This randomized phase III trial is studying surgery followed by combination chemotherapy to see how well it works compared to combination chemotherapy followed by surgery in treating patients with locally advanced stomach cancer.

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: Taxotere-Cisplatin-5FU Drug: Immediate surgery Phase 3

Detailed Description:


  • Compare, by intention to treat analysis, feasibility and efficacy of 4 courses of docetaxel, cisplatin, and fluorouracil as preoperative or postoperative chemotherapy in patients with locally advanced operable gastric carcinoma.
  • Evaluate the predictive values of some biological and molecular tumor parameters on response to chemotherapy, metastasis and survival in this patient population.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to study center, tumor site (affecting the Z-line (cardia carcinoma Siewart II and III) vs rest of the stomach), and nodal status (positive vs negative). Patients are randomized to either preoperative chemotherapy followed by surgery (arm I) or surgery followed by postoperative chemotherapy (arm II).

  • Arm I: Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 4 hours on day 1, and fluorouracil IV continuously on days 1-14 every 3 weeks. Patients are evaluated after 2 courses and patients with progressive disease proceed to immediate surgery. Otherwise, treatment continues for a total of 4 courses in the absence of unacceptable toxicity or disease progression. Between 3-5 weeks following day 1 of the last course of chemotherapy, patients undergo gastric resection.
  • Arm II: Patients undergo immediate gastric resection. Beginning 3-6 weeks after surgery, patients receive 4 courses of docetaxel, cisplatin, and fluorouracil as in arm I.

Quality of life is assessed before the first and third courses of chemotherapy, before and after surgery, and then at 1, 3, and 6 months.

Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 240 patients (120 per arm) will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Trial of Preoperative vs. Postoperative Chemotherapy With Taxotere-Cisplatin-5FU (TCF) in Patients With Locally Advanced Operable Gastric Carcinoma
Study Start Date : November 1999
Actual Primary Completion Date : November 2005
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Active Comparator: Taxotere-Cisplatin-5FU preoperatively
TCF preoperatively
Drug: Taxotere-Cisplatin-5FU

Active Comparator: Immediate surgery followed by TCF
Surgery followed by Taxotere-Cisplatin-5FU
Drug: Immediate surgery
Immediate surgery followed by Taxotere-Cisplatin-5FU

Primary Outcome Measures :
  1. Event-free survival

Secondary Outcome Measures :
  1. Overall survival
  2. Time to treatment failure measured after completion of study treatment
  3. Toxicity measured after completion of study treatment
  4. Rate of complete resection (RO) and postoperative mortality as measured after surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed locally advanced gastric carcinoma that is considered operable

    • T3-4, Nx, M0 OR
    • Tx, N+, M0
  • Lymph nodes considered positive by sonography should be at least 2 of the following:

    • Round
    • Echopoor
    • Sharp borders
    • At least 0.5 cm
  • No distant metastases, including peritoneal carcinomatosis

    • CT scan and peritoneal lavage mandatory



  • 18 to 75

Performance status:

  • 0-2

Life expectancy:

  • Greater than 12 weeks


  • WBC at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin normal
  • AST or ALT no greater than 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2.5 times ULN


  • Adequate renal function within limits to allow for treatment with cisplatin


  • No unstable cardiac disease requiring treatment
  • No congestive heart failure or angina pectoris even if medically controlled
  • No significant arrhythmias
  • No myocardial infarction within past 6 months
  • Ejection fraction greater than 50% on cardiac sonography or MUGA scan


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other prior malignancy except basal cell carcinoma of the skin or adequately treated carcinoma in situ of the cervix
  • No grade 2 or greater peripheral neuropathy of any origin (e.g., alcohol, diabetic)
  • No history of anaphylaxis
  • No other serious concurrent illness or medical condition that would preclude study therapy
  • No history of significant neurologic or psychiatric disorders (e.g., psychotic disorders, dementia, or seizures)


Biologic therapy:

  • No concurrent biologic therapy for gastric carcinoma


  • No other concurrent chemotherapy for gastric carcinoma

Endocrine therapy:

  • No concurrent endocrine therapy for gastric carcinoma


  • No concurrent radiotherapy for gastric carcinoma


  • See Disease Characteristics


  • At least 30 days since prior treatment in a clinical trial
  • No other concurrent experimental drugs
  • No other concurrent anticancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00005060

European Institute of Oncology
Milan, Italy, 20141
Hopital Cantonal Universitaire de Geneve
Geneva, Switzerland, CH-1211
Zentrum fuer Tumordiagnostikund Praevention
St. Gallen, Switzerland, CH-9006
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Study Chair: Rudolf Morant, MD Tumor Zentrum ZeTup St. Gallen und Chur

Responsible Party: Swiss Group for Clinical Cancer Research Identifier: NCT00005060     History of Changes
Other Study ID Numbers: SAKK 43/99
SWS-SAKK-43/99 ( Other Identifier: SAKK )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: May 15, 2012
Last Verified: May 2012

Keywords provided by Swiss Group for Clinical Cancer Research:
stage II gastric cancer
stage III gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action